dr grimm on unmet needs after progression to mcrpc following arpi plus chemo
Published 1 month ago • 19 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
3:00
dr grimm on the rationale for conducting a post-hoc analysis of arasens in mhspc
-
1:12
dr. graff underscores unmet needs in esr1-mutated breast cancer
-
0:49
unmet needs for patients with prostate cancer
-
2:04
dr. azad on unmet needs in metastatic hormone-sensitive prostate cancer
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
2:04
dr. beer on the design and results of the prevail trial
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
2:04
unmet need in bladder cancer
-
2:17
custirsen shows no survival benefit in metastatic prostate cancer
-
4:12
myc and multiple myeloma: drugging the undruggable
-
6:02
unmet needs in recurrent hnscc
-
0:27
immortal trial - why some patients can't get chemo
-
3:16
counseling patients with mcrpc
-
1:24
dr. posadas on a phase ib study of abiraterone plus docetaxel for mcrpc
-
0:47
tanya dorff, md, on impressions of the card study investigating the role of cabazitaxel in mcrpc
-
5:28
unmet needs for metastatic breast cancer
-
1:10
unmet needs in immunotherapy for prostate cancer
-
1:55
dr. sweeney on chemotherapy versus abiraterone for mcrpc
-
3:49
unmet needs in r/r her2 metastatic breast cancer